J B CHEMICALS AND PHARMA Stock Context for AI Screening

J B CHEMICALS AND PHARMA is a mid-cap stock in Healthcare. This page summarizes key screening signals for J B CHEMICALS AND PHARMA, including recent returns, momentum indicators, valuation ratios, liquidity, and growth metrics. Gimli uses this context to help users ask natural-language stock screening questions across Indian equities.

Open interactive JBCHEPHARM stock page

Price

₹2,435.80

1W return

+6.00%

1M return

+12.10%

3M return

+25.40%

6M return

+27.46%

1Y return

+49.86%

Market cap

₹39,108.89 cr

55.12

9.40

ROE

+18.69%

ROCE

+25.13%

RSI

80.19

Turnover

₹284.84 cr

Why it can matter in screens

Momentum: JBCHEPHARM is above 50DMA, above 200DMA; RSI is 80.19.
Returns: 1D +0.57%, 1W +6.00%, 1M +12.10%, 3M +25.40%, 1Y +49.86%.
Trend levels: 52W high ₹2,435.80, 52W low ₹1,608.60, off high +0.00%.
Liquidity: latest turnover is ₹284.84 cr; volume vs 20D is +3.45%.
Valuation/profitability: PE 55.12, PB 9.40, ROE +18.69%, ROCE +25.13%.
Growth: 3Y sales CAGR +9.36%, 3Y profit CAGR +20.07%.

Financials and Ownership

Quarterly income statement

Period	Revenue	EBITDA	PAT	EPS
2026-03-31	904.23 cr	185.93 cr	101.37 cr	6.35
2025-12-31	1,064.72 cr	314.10 cr	197.89 cr	12.63
2025-09-30	1,084.90 cr	324.94 cr	207.82 cr	13.29
2025-06-30	1,093.94 cr	315.42 cr	202.38 cr	12.99
2025-03-31	949.48 cr	240.92 cr	145.69 cr	9.36
2024-12-31	963.49 cr	262.51 cr	162.49 cr	10.46
2024-09-30	1,000.62 cr	280.47 cr	174.57 cr	11.24
2024-06-30	1,004.40 cr	286.26 cr	176.83 cr	11.39

Annual income statement

Year	Revenue	EBITDA	PAT	EPS
2026-03-31	4,076.20 cr	1,140.28 cr	709.47 cr	42.23
2025-03-31	3,862.04 cr	1,069.12 cr	659.58 cr	42.45
2024-03-31	3,447.67 cr	933.48 cr	552.63 cr	35.66
2023-03-31	3,116.51 cr	705.05 cr	409.84 cr	26.50
2022-03-31	2,228.49 cr	582.68 cr	361.00 cr	24.93

Balance sheet

Period	Assets	Cash	Debt	Equity
2026-03-31	4,968.65 cr	110.18 cr	3.59 cr	4,159.22 cr
2025-03-31	4,273.78 cr	115.09 cr	27.89 cr	3,433.32 cr
2024-03-31	3,994.13 cr	88.22 cr	377.66 cr	2,923.33 cr
2023-03-31	3,553.87 cr	76.93 cr	572.45 cr	2,480.35 cr
2022-03-31	2,607.40 cr	56.54 cr	54.56 cr	2,138.61 cr

Cash flow

Period	OCF	FCF	Cash change
2026-03-31	703.92 cr	620.73 cr	n/a
2025-03-31	902.45 cr	782.14 cr	n/a
2024-03-31	800.61 cr	539.24 cr	n/a
2023-03-31	625.61 cr	-139.33 cr	n/a
2022-03-31	170.14 cr	-536.65 cr	n/a

Shareholding Trend

Period	Promoter	FII/FPI	DII	MF	Retail	Pledge
2026-03-31	+48.80%	+16.33%	+21.38%	+19.00%	+13.48%	+0.00%
2026-01-23	+48.78%	+14.56%	+22.71%	+19.22%	+13.95%	+0.00%
2025-12-31	+47.55%	+14.88%	+23.36%	+19.61%	+14.22%	+0.00%
2025-09-30	+47.56%	+15.30%	+22.83%	+19.15%	+14.30%	+0.00%
2025-06-30	+47.73%	+17.77%	+19.63%	+16.27%	+14.88%	+0.00%
2025-03-31	+47.84%	+18.30%	+18.72%	+16.26%	+15.14%	+0.00%

Industry Peers

Symbol	Name	Mcap	PE	ROE	1Y
SUNPHARMA	SUN PHARMACEUTICAL IND L	453,042.43 cr	39.400236	+14.71%	+12.90%
DIVISLAB	DIVI S LABORATORIES LTD	179,324.04 cr	69.830233	+16.19%	-2.64%
TORNTPHARM	TORRENT PHARMACEUTICALS L	164,701.07 cr	76.144739	+17.18%	+46.47%
APOLLOHOSP	APOLLO HOSPITALS ENTER. L	125,861.94 cr	64.267738	+21.03%	+15.71%
CIPLA	CIPLA LTD	115,660.88 cr	29.801362	+11.79%	-3.80%
ZYDUSLIFE	ZYDUS LIFESCIENCES LTD	115,515.66 cr	23.036787	+17.93%	+16.76%
LUPIN	LUPIN LIMITED	112,429.39 cr	21.054508	+26.83%	+27.93%
DRREDDY	DR. REDDY S LABORATORIES	112,317.04 cr	26.207396	+11.94%	+5.08%

Try these prompts

Analyze J B CHEMICALS AND PHARMA with valuation, momentum and industry peers
Compare JBCHEPHARM with other Healthcare stocks
Show mid-cap stocks in Healthcare above 50DMA with positive 1M return
Find Healthcare stocks with improving momentum and reasonable valuation

Related screen ideas

Data snapshot: 2026-07-08. Not investment advice.